Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy by Jumpertz von Schwartzenberg, R. et al.
Open Access
R Jumpertz von
Schwartzenberg and others
Palliative treatment of
uncontrollable hypercalcemia
ID: 15-0082; November 2015
DOI: 10.1530/EDM-15-0082Palliative treatment of uncontrollable
hypercalcemia due to parathyrotoxicosis:
denosumab as rescue therapyReiner Jumpertz von Schwartzenberg1, Ulf Elbelt1, Manfred Ventz1, Knut Mai1,
Tina Kienitz1, Lukas Maurer1, Thomas Rose2, Jens C Ru¨ckert3, Christian J Strasburger1
and Joachim Spranger1
1Department of Endocrinology and Metabolic Diseases 2Division of Rheumatology and Clinical Immunology,
Medical Department 3Department of General, Visceral, Vascular and Thoracic Surgery,
Charite´ - Universita¨tsmedizin, Charite´platz 1, 10117 Berlin, GermanyThis work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivs 3.0
Unported License.
q 2015 The authorsCorrespondence
should be addressed
to R Jumpertz von
Schwartzenberg
Email
reiner.jumpertz@charite.deAbstractParathyroid carcinoma is a rare disease leading to severe hypercalcemia due to hyperparathyroidism. Surgery is the
primary treatment option. A more progressive form of the disease is characterized by parathyrotoxicosis, and subsequent
hypercalcemia is the most common cause of death. We report a case presenting with severe hypercalcemia due to
parathyrotoxicosis from parathyroid carcinoma treated for the first time using the monoclonal antibody denosumab as a
rescue therapy and present long-term follow-up data. The 71-year-old patient presented with severe hypercalcemia due to
metastatic parathyroid carcinoma. Despite undergoing treatment with bisphosphonates, cinacalcet hydrochloride, and
forced diuresis, the patient‘s condition deteriorated rapidly due to resistant hypercalcemia. Surgery performed because
of spinal metastasis and forced diuresis lowered calcium levels, albeit they remained in the hypercalcemic range and
significantly increased when forced diuresis was stopped. Considering a palliative situation to overcome hypercalcemia, we
decided to administer denosumab, a monoclonal antibody that binds to the receptor activator of nuclear factor-kappa B
ligand. After a single subcutaneous administration of 60 mg denosumab, calcium levels normalized within one day.
Subsequent denosumab injections led to permanent control of serum calcium for more than 2 years despite rising
parathyroid hormone levels and repeated surgeries. Together with recent cases in the literature supporting our observation,
we believe that denosumab is relevant for future trials and represents an effective tool to control hypercalcemia in patients
with advanced stages of parathyroid cancer.Learning points:
† Severe hypercalcemia is the most common cause of death in patients with parathyroid carcinoma.
† The monoclonal antibody denosumab rapidly lowered severely elevated serum calcium levels due to
parathyrotoxicosis.
† Denosumab was effective in the long-term treatment of hypercalcemia despite progression of parathyroid
carcinoma.http://www.edmcasereports.com
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Parathyroid carcinoma is a rare condition occurring in
0.7–2.1% of patients with primary hyperparathyroidism.
As of today, surgery is the only known curative treatment.
However, pre-surgical differentiation of excess para-
thyroid hormone (PTH) due to parathyroid adenoma or
carcinoma is challenging. Observational studies have
demonstrated that 76.6–80% of patients with parathyroid
carcinoma have a tumor size of O3 cm and 85% had pre-
surgical calcium concentrations of O3 mmol/l (1). Thus,
large tumors and severe hypercalcemia indicate higher
risk for parathyroid cancer. If parathyroid cancer exists,
en bloc resection of the tumor with centrocervical
lymphadenectomy is the recommended treatment. None-
theless, cancer is not suspected pre-surgically very often,
and local excision is still the most common method of
surgery despite higher risk rates of death and recurrence
of the tumor (1, 2). In case of tumor recurrence, local
resection of the tumor and metastases is the recom-
mended treatment approach. In some cases reduction
of tumor mass may also include radiotherapy, cryoabla-
tion, or embolization. In advanced stages of the disease,
reduction of tumor mass may no longer be a feasible
treatment option, and in these palliative cases, severe
hypercalcemia represents the most common cause of
death (3). Malignant PTH-driven hypercalcemia is the
main cause of bone pain and pathological fractures in
these patients, as well as pancreatitis, peptic ulcer, and
anemia, and eventually leads to severe end-organ
damage, such as renal faliure (4). The mainstay of
palliative care for patients with advanced disease there-
fore includes control of bone loss and prevention of
severe hypercalcemia to warrant quality of life. Various
calcium-lowering drugs have been used in patients with
parathyroid cancer such as mithramycin, plicamycin,
gallium nitrate, and calcitonin combined with gluco-
corticoids leading to rather transient changes in calcium
levels (4, 5). However, new drugs such as calcimimetics
are more effective in lowering calcium levels and bear less
side effects. Palliative medical therapy in parathyroid
cancer patients today is mainly based on the use of
intravenous bisphosphonates and calcimimetics such as
cinacalcet hydrochloride.
Here, we report a case with severe parathyrotoxicosis
due to advanced non-resectable parathyroid carcinoma
treated with the additional administration of a new drug,
the monoclonal antibody denosumab, for management of
calcium levelshttp://www.edmcasereports.comCase presentation and treatment
The 71-year-old male patient was first diagnosed with
parathyroid cancer in 1992. Subsequent surgical treatment
included local resection of the tumor and complete
thyroidectomy leaving the patient with permanent palsy
of the left laryngeal nerve. Histological analysis confirmed
parathyroid carcinoma. Hereafter, the tumor was in
remission for 13 years. In 2005, local recurrence of the
tumor was observed in the thyroid bed. This was followed
by complete resection and subsequent local radiation
therapy. In December 2008, the patient underwent
cervical lymphadenectomy dorsal to the right clavicle
where no tumor tissue was found. One month later, the
cancer metastasized cranially to the jugular notch of the
sternum and was resected in toto. In 2009, osseous
metastases occurred in the second rib on the left and
seventh rib on the right side as well as in the body of the
sternum. By the end of 2009, pulmonary masses highly
suggestive of metastases were seen. Additionally, pulmon-
ary embolism was diagnosed requiring subsequent antic-
oagulation. In 2010, the osseous metastases in the ribs and
sternum were resected completely during three different
interventions, followed by local radiation therapy. In 2011
pulmonary metastases remained stable, but after sub-
sequent local progression had to be resected in toto by the
beginning of 2012. For prevention of hypercalcemia and
bone loss, the patient was treated with 4 mg zolendronic
acid intravenously every four weeks and 90 mg daily oral
administration of the calcimimetic cinacalcet hydro-
chloride. The patient did not tolerate higher doses of
cinacalcet due to increased nausea. Nonetheless, in the
course of the year 2012, a profound increase in serum
calcium levels occurred accompanied by a rise in PTH
levels (Fig. 1). Simultaneously, the patient suffered from
increasing abdominal pain, nausea, and lost w10 kg of
body weight over 1 year presenting a cachectic condition
(54 kg body weight). By February 2013, serum calcium
levels had risen to 3.7 mmol/l and PTH concentrations
increased to 429 ng/l while the patient continued to suffer
from severe abdominal pain, further weight loss, and
obstipation. At this time, the patient was admitted to our
inpatient unit for severe parathyrotoxicosis. During the
course of the inpatient stay, forced diuresis with 3000 ml
of fluids (NaCl 0.9%) and 40 mg of furosemide twice daily
was administered for kidney protection and mainly for
control of calcium levels. During this regimen, serum
calcium levels decreased slightly; however, they remained
at 3.0 mmol/l and thus above normal range (see Fig. 1).
Nonetheless, the condition of the patient did not improve2
Serum calcium and parathyroid hormone over time
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Figure 1
Serum calcium and parathyroid hormone levels over time. Albumin-
corrected serum calcium concentrations in mmol/l and parathyroid
hormone concentrations in our patient are depicted over time. Normal
range for calcium is shown according to our laboratory standards (normal
range for calcium: 2.20–2.55 mmol/l; normal range for PTH: 10–65 ng/ml).
Denosumab injections are indicated by black arrows; the patient
additionally received 90 mg of cinacalcet daily. In April 2014, cinacalcet
dosage was increased to 180 mg daily, which was not tolerated by the
patient and subsequently continued at 90 mg daily. * represents resection
of spinal metastasis at vertebra 6. # represents resection of a supraclavicular
metastasis on the left side without significant reduction in PTH levels.
§ represents resection of three cervical metastases on the left side. Forced
diuresis comprised infusion of 2000–3000 ml of 0.9% sodium chloride
solution and 80 mg furosemide daily.
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controlled 18F-fluordesoxyglucose positron emission
tomography (PET) showed increased glucose uptake in
the sixth thoracic vertebra (Fig. 2). The patient underwent
vertebral surgery for resection of the vertebral mass and
dorsal stabilization. Histology confirmed a metastasis from
parathyroid carcinoma. After surgery, PTH levels
decreased to 210 ng/l. However, despite forced diuresis
and additional infusion of 4 mg zolendronic acid, calcium
levels declined only slightly and mostly remained in the
hypercalcemic range. Review of the neck region in PET-
imaging raised suspicion of local recurrence on the right
side of the thyroid bed, although no distinct activity peak
could be identified (Fig. 3). However, venous catheteriza-
tion confirmed excess PTH on the right side of the neck.
Due to repeated surgery and subsequent scar tissue
development in this area as well as left laryngeal nerve
palsy, additional neck surgery did not seem beneficial for
the patient. One month after vertebral surgery, calcium
levels increased again to 3.1 mmol/l (Fig. 1). Taken
together, the patient was facing rising calcium levels
despite surgery, ongoing forced diuresis, intravenous
bisphosphonate therapy, and daily oral administration
of cinacalcet hydrochloride. At this point, we did not have
further treatment options and searched the literature forhttp://www.edmcasereports.comalternative approaches. Based on an article by Boikos and
Hammers who had recently used denosumab in a patient
with hypercalcemia from metastatic renal cell carcinoma
(6), we initiated the off-label administration of denosu-
mab, a monoclonal antibody that binds to the receptor
activator of nuclear factor-kappa B ligand (RANKL) in our
patient. Denosumab is a bone mineral density modifying
full human antibody (IgG2) with high affinity to RANKL,
thereby inhibiting the RANKL–RANK interaction. RANKL
is secreted by osteoblasts upon stimulation by PTH leading
to differentiation and stimulation of osteoclasts. Thus,
denosumab inhibits RANKL-mediated bone resorption
and thereby promotes reduction in serum calcium
concentrations. We administered 60 mg of denosumab
subcutaneously in our patient.Outcome and follow-up
Within one day after the denosumab injection, serum
calcium levels normalized and remained stable despite
discontinuation of forced diuresis (Fig. 1). We discharged
the patient from our inpatient unit two days later. During
regular outpatient visits, calcium levels remained stable
between 2.6 and 2.7 mmol/l for four months (Fig. 1).
During this time, the condition of the patient3
Figure 2
Sagittal PET-CT image of a spine metastasis. Location of spinal metastasis
(red arrow) in a CT-merged 18F-fluordesoxyglucose positron emission
tomography (PET).
Figure 3
Transverse PET-CT image of the neck/thorax chest region. Transverse picture
of an area in the neck/chest region with potentially increased local glucose
uptake (red arrow) of a CT-merged 18F-fluordesoxyglucose positron
emission tomography (PET), suspicious but not conclusive for local
recurrence.
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and improved appetite and weight gain. After a new rise in
calcium levels, another 60 mg of denosumab were
injected, yet again followed by reduced and stable serum
calcium levels over months despite high PTH levels. In
total, six doses of denosumab during the following
months led to stable calcium levels without further need
for inpatient treatment. By November 2014, PTH levels
peaked at 413 pg/ml; however, another denosumab
injection sufficiently stabilized serum calcium. Clinically
relevant side effects were not observed. Resection of a new
supraclavicular metastasis on the left side in August 2014
did not affect PTH levels significantly. In February 2015,
another three cervical metastases were removed. Again,
after repeated Denosumab injections, calcium levels
remained above normal but stable until the last follow-
up in May 2015. The follow-up period included 25 months
in total after the first denosumab injection.http://www.edmcasereports.comDiscussion
We reported a case presenting with severe treatment-
resistant hypercalcemia secondary to parathyrotoxicosis
that responded to administration of the RANKL-antibody
denosumab with rapid and persistent reduction in serum
calcium levels. We observed no relevant side effects.
Subcutaneous administration of the antibody has
been proven to be effective in increasing bone mineral
density and inhibiting bone resorption in post-menopau-
sal women, as well as in reducing calcium levels in patients
with hypercalcemia due to hematologic cancers or bone
metastases of solid tumors (7, 8). However, to date, no
clinical studies have addressed the efficacy of denosumab
in reducing calcium levels in patients with severe PTH
excess due to parathyroid carcinoma. One interesting
aspect of this case is how rapidly calcium levels dropped to
normal ranges despite ongoing parathyrotoxicosis.
However, during this phase, we cannot clearly discrimi-
nate the calcium lowering effects of the surgery, zolen-
dronic acid, and denosumab. Calcium levels had been
increasing despite zolendronic acid infusions over the
previous months, and although calcium levels decreased
after surgery, they remained in the hypercalcemic range
and could not be further reduced by forced diuresis. The
temporal association of denosumab injection and drop in
calcium levels is highly indicative of an acute effect of
denosumab. An early case report by Boikos and Hammers
from 2012 demonstrated calcium lowering effects of
denosumab in a patient with pulmonary metastases of4
Table 1 Current literature on the use of denosumab in hypercalcemia due to parathyrotoxicosis.
References Hypercalcemia due to Origin Injections Patient doses Accumulated dose Follow-up
(6,8) Parathyroid hormone
related peptide
Renal cell carcinoma 1 120 mg 120 mg 1 month
(9) Parathyroid hormone Parathyroid carcinoma 3 120 mg 360 mg 10 months
(11) Parathyroid hormone Parathyroid carcinoma 15 60 mg, 120 mg 1080 mg 23 months
(12) Parathyroid hormone Parathyroid carcinoma 7 120 mg 840 mg 14 months
(10) Parathyroid hormone Parathyroid carcinoma 5 60 mg, 120 mg 480 mg 7 months
Present Case
Report
Parathyroid hormone Parathyroid carcinoma 9 60 mg 540 mg 26 months
Comparison of the current literature regarding denosumab application, dosage, and follow-up time.
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cemia secondary to excess of PTH-related peptide. Inter-
estingly, similar to our observation, calcium levels
dropped rapidly within 2 days after denosumab adminis-
tration and remained stable for about a month (6).
A similar observation was made in a patient with para-
thyroid cancer, where the authors used much higher
initial doses of denosumab. Again, calcium levels dropped
rapidly despite rising PTH levels (9). Unfortunately, longer
follow-up was not possible because the patient died due to
disease progression. Recently, Karruppiah et al. have made
similar observations in a patient with parathyrotoxicosis
due to non-localizable parathyroid carcinoma using
higher doses (120 mg) of denosumab (10). Another
important learning point however is that repeated
denosumab injections in relatively low doses, such as in
our case, can be sufficient for maintaining controlled
calcium levels over months or even years (although
surgical interventions most likely had an additional
impact). This is supported by a recent case report, where
the authors showed rapid declines in serum calcium upon
denosumab administration and persistent normocalcemia
over months (11). After recurring calcium peaks due to
rising PTH levels, higher doses of denosumab and more
frequent applications again lead to normalization of
serum calcium. Additionally, Itoshima et al. have also
used denosumab in a patient with even more severe
parathyrotoxicosis than in our case, and frequent admin-
istration of denosumab, albeit in a higher dosage
(120 mg), was sufficient to maintain normal calcium levels
(12). In our case, denosumab dosage was lower and
administration frequency was marginally higher;
however, calcium levels were slightly above normal, and
thus, higher doses also seem feasible in our patient.
Together with Vellanki et al., our case is the only one
with a long term follow-up after the first denosumab
injection. For an overview of the current literature and
denosumab dosages see Table 1.http://www.edmcasereports.comTaken together, 1) subcutaneous application of
denosumab led to rapid and permanent reduction in
serum calcium levels in our case with parathyrotoxicosis
secondary to parathyroid carcinoma. 2) Long term follow-
up showed that repeated low-dose denosumab injections
were effective in maintaining stable calcium levels despite
excess PTH levels from parathyroid carcinoma.Declaration of interest
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